MAPT and Mental deterioration: Even though p-Tau217 has shown better performance in the prediction of future cognitive decline in pre-symptomatic and early stages [18, 34], p-Tau181 provides advantages from its cohesiveness from its comparability with traditional gold standard biomarkers, such as CSF p-Tau181 quantification and other modalities (i.e., Tau-PET imaging), and the possibility of performing confirmatory studies by post-mortem neuropathology.